Pharma Market Briefing: Q2 2026 USFDA Type II DMF Filings, 505(b)(2) Strategy & EPO Updates
Pharma Regulatory & IP Insights: Q2 2026 USFDA DMF Trends, 505(b)(2) Value Drivers, and EPO Process Patent Rulings
Welcome to the latest Sidvim LifeSciences market briefing
1. Q2 CY 2026 USFDA Type II Drug Master File (DMF) Submissions Overview
Monitoring quarterly DMF filings offers valuable business insights on the generic pipeline and highlights opportunities for API suppliers to provide APIs to formulators targeting upcoming Paragraph IV/NCE-1 filings in the US.
During Q2 2026 (April 1 to June 30, 2026), 243 Type II DMFs were submitted to the USFDA by 165 companies.Geographic Distribution: China Maintains Volume Lead
Over the last 2–3 years, Chinese API manufacturers have consistently outpaced Indian filers in sheer filing volume
| Country | Number of Filings | Share (%) | Unique Companies |
| China | 151 | 62% | 95 |
| India | 62 | 26% | 44 |
| United States | 13 | 5% | 12 |
| Netherlands | 3 | 1% | 2 |
| South Korea | 3 | 1% | 3 |
| United Kingdom | 3 | 1% | 2 |
| Germany | 2 | 1% | 2 |
| Others (Japan, Italy, Slovakia, Turkey, etc.) | 6 | 2% | 6 |
| Total | 243 | 100% | 165 |
Source: Sidvim Analysis of USFDA Type II DMF Submissions (Q2 2026)
Key High-Value NCE-1 Pipeline Highlights
A selection of high-value filings targeting recently approved New Chemical Entities (NCEs) approaching their 4-year Paragraph IV / NCE-1 filing eligibility window includes:
| Active Ingredient (API) | Reference Brand (Sponsor) | Indication | Target NCE-1 Date | Key Filers & IP Insights |
| Resmetirom | Rezdiffra (Madrigal) | NASH / MASH | Mar 2028 | Zydus, Lewens Labs: Highly competitive space (18 total DMFs) |
| Iptacopan HCl | Fabhalta (Novartis) | PNH & IgA Nephropathy | Dec 2027 | Alembic, Shandong ChemInspire: Innovator crystalline hydrate patent runs to 2041; generic filers must offer non-infringing polymorphs to file on the NCE-1 date |
| Elacestrant Dihydrochloride | Orserdu (Stemline) | ER+/HER2- Breast Cancer | Jan 2027 | Biophore India (2 filings), Chongqing Huapont: Biophore filed separate DMFs for API and Pre-mix to potentially circumvent innovator polymorphic patent US 10,385,008 (exp. 2038) |
2. General Industry & Regulatory Updates
Novo Nordisk Sues Eli Lilly Over Weight-Loss Ads: Novo Nordisk has initiated legal action against Eli Lilly, alleging false advertising and unfair competition regarding marketing claims for Zepbound® and Mounjaro®
. The suit underscores the intensifying commercial rivalry for dominance in the multi-billion-dollar U.S. metabolic and obesity care market . 505(b)(2) Pathway as an Engine of Value Creation: In a risk-averse investment climate, the USFDA 505(b)(2) regulatory pathway offers a compelling balance of reduced development risk and capital efficiency
. By leveraging existing clinical safety and efficacy data from reference drugs, sponsors can shorten development schedules by several years and cut costs by tens to hundreds of millions of dollars compared to traditional 505(b)(1) NDAs . Success requires early strategic alignment on bridge-data adequacy and clear ROI models .
3. Intellectual Property Focus
EPO Board of Appeal Decision: T 1164/24 (Nouryon v. United Initiators)
On May 11, 2026, the Technical Board of Appeal of the European Patent Office issued a key decision regarding Nouryon’s EP 3728187 ("Process for preparing a powdery organic peroxide formulation")
Key Findings
Sufficiency of Disclosure (Art. 83 / 100(b) EPC): The Board affirmed that "preparing a mixture" in process claims encompasses sequential addition of components and holding the mixture at a temperature, following claim construction standards in G 1/24 and T 243/23
. Lack of Inventive Step in Granted Claims (Art. 56 EPC): While granted claim 1 was inventive over document D1, it failed against document D2
. Simply substituting phthalate phlegmatizers with non-toxic benzoates addresses safety concerns but represents an obvious choice unless accompanied by unexpected technical performance data . Patent Saved via Quantitative Narrowing: Under Auxiliary Request IV, limiting surfactant levels to 0.002–0.020 wt% (below D2's 0.032 wt% example) established a novel, non-obvious technical effect—namely, superior particle size distribution, reduced foaming, and improved filtration behaviour.
Key Strategy Takeaway: When defending chemical process patents against legacy prior art, replacing hazardous ingredients solves only an "obvious substitution" problem. To secure robust, defensible claims, process developers must tie chemical modifications to tightly defined functional additive ranges that demonstrably resolve manufacturing defects.
#USFDADMF, #PharmaRegulations, #GenericDrugs, #IntellectualProperty, #SidvimPharmaUpdate
----------XX-----------XX--------------
Thank you for reading the summary. I encourage you to read the detailed article below.
Contents
Q2 CY 2026 USFDA Type II Drug Master File (DMF) Submissions Overview
General information
Novo sues Lilly, claiming misleading ads in weight-loss drug battle
Opinion: The FDA’s 505(b)(2) pathway is an underestimated engine of value creation
Intellectual Property
EPO Board of Appeal Decision: T 1164/24 (Nouryon v. United Initiators)
Q2 CY 2026 USFDA Type II Drug Master File (DMF) Submissions Overview
General information
Novo sues Lilly, claiming misleading ads in weight-loss drug battle
- Novo accuses Lilly of claiming its weight-loss medicines outperform Novo's
- Danish drugmaker alleges Lilly violated ad and unfair competition laws in Zepbound and Mounjaro ads
- Novo, Lilly locked in battle to dominate U.S. obesity drug market
News here
Opinion: The FDA’s 505(b)(2) pathway is an underestimated engine of value creation
In a capital environment defined by caution, scepticism, and heightened demand for controlled risk, the FDA’s 505(b)(2) pathway stands as one of the few remaining regulatory levers capable of accelerating innovation with some level of capital protection. Designed to enable sponsors to leverage existing efficacy and safety data for approved drugs while introducing meaningful modifications, the pathway can reduce development timelines for new therapies by several years and cut costs by tens to hundreds of millions of dollars relative to a 505(b)(1) New Drug Application.
The sponsor of a 505(b)(2) application needs to carefully consider the strategy, and factors such as: what data are available, and are those data sufficient for the regulatory agency to bridge to the new application? Is the return on investment sufficient for the estimated time and costs of development?
News here
Intellectual Property
EPO Board of Appeal Decision: T 1164/24 (Nouryon v. United Initiators)
On May 11, 2026, the Technical Board of Appeal of the European Patent Office (EPO) issued its decision in regarding European Patent No. 3728187 ("Process for preparing a powdery organic peroxide formulation"), held by Nouryon Chemicals International B.V. Following an appeal by opponent United Initiators GmbH, the Board set aside the decision of the Opposition Division and ordered the patent to be maintained in amended form based on Auxiliary Request IV.
Key Issues & Findings
1. Admissibility of the Appeal
Patent proprietor Nouryon requested that opponent United Initiators’ appeal be dismissed as inadmissible, alleging that the opponent merely repeated its opposition arguments. The Board rejected this challenge, ruling that the statement of grounds adequately addressed the Opposition Division's reasoning. The appeal was declared admissible.
2. Sufficiency of Disclosure (Article 83 / Article 100(b) EPC)
United Initiators argued that the patent lacked sufficient disclosure, asserting that the examples did not fall strictly within claim 1 because ingredients were added sequentially rather than simultaneously, and that heating was not performed as a discrete, separate step.
The Board rejected these arguments based on standard claim construction principles (citing Enlarged Board decision G 1/24 and T 243/23):
- Step (a) (Reaction Mixture): Claim 1 does not mandate simultaneous addition of components; sequential addition is fully encompassed and supported by paragraph [0039] of the description.
- Step (b) (Heating): The phrase "heating... at a temperature" encompasses holding or maintaining the mixture within the specified 5-50 °C range.
- The Board held that the skilled person possesses sufficient general technical guidance to perform the process and adapt workup/purification procedures across the claimed breadth. The ground for opposition under Article 100(b) EPC was rejected.
3. Main Request (Patent as Granted): Lack of Inventive Step (Article 56 EPC)
Claim 1 of the main request defined a reaction mixture containing 0.002–0.20 wt% surfactant and 1–25 wt% phlegmatizer selected from specific benzoates and toluates.
- Assessment vs. Document D1 (WO 2012/159726 A1): D1 uses 0.6 wt% surfactant. Comparative Example C in the patent demonstrated that lowering surfactant content to the claimed range reduced fine particles (<100 microns) and suppressed foaming, improving filtration and yield. The Board concluded the main request was inventive over D1.
- Assessment vs. Document D2 (DE 1768199 A1): D2 discloses a one-pot reaction using 9.5 wt% acid chloride but employs dicyclohexyl phthalate as the phlegmatizer.
- Fatal Defect: While switching from phthalates to non-toxic benzoates addresses environmental/health concerns, Nouryon provided no evidence demonstrating improved particle size distribution, yield, or foaming over D2. Because replacing toxic phthalates with known benzoate substitutes (such as glyceryl tribenzoate) was obvious to a skilled person seeking a safer alternative, claim 1 of the main request lacked an inventive step over D2 in view of D1.
Auxiliary Request IV: Maintenance in Amended Form
Nouryon’s Auxiliary Request IV restricted the allowable surfactant concentration to a narrower window: 0.002–0.020 wt% (down from 0.002–0.20 wt%).
- Amendments (Article 123(2) EPC): The Board satisfied itself that the restricted surfactant range (0.002–0.020 wt%) was directly and unambiguously supported by page 5 of the original application as filed.
- Inventive Step over D2: In addition to replacing the phthalate phlegmatizer, the maximum surfactant limit in Auxiliary Request IV (0.020 wt%) is explicitly lower than the surfactant concentration disclosed in D2’s example (0.032 wt%).
- Technical Effect: The Board accepted that reducing the surfactant level below D2's disclosure directly improves particle size distribution, reduces foaming, and enhances filtration behaviour. D2 offers no teaching or motivation to reduce surfactant levels to achieve these operational improvements.
Conclusion & Legal Outcome
The Board of Appeal remitted the case to the Opposition Division with the order to maintain European Patent No. 3728187 in amended form based on claims 1 to 12 of Auxiliary Request IV and the description adapted during oral proceedings.
Strategic Takeaway for Chemical Process Developers
This ruling illustrates the importance of quantitative ranges when defending process patents against legacy prior art. Merely replacing a hazardous component (like phthalates) with an established alternative solves only an "obvious alternative" problem unless accompanied by unexpected performance data. However, combining the replacement with a strictly restricted functional additive range (e.g., ultralow surfactant content) that solves real-world processing defects (foaming and fine particle generation) successfully establishes patentability.
Decision here
